Jun Cheng, Min Li, Ping Gao, Jin-ling Dong and Qi Wang
1. Chang ML, Yeh HC, Tsou YK, Wang CJ, Cheng HY, Sung CM, et al. HCV core-induced nonobese hepatic steatosis is associated with hypoadiponectinemia and is ameliorated by adiponectin administration. Obesity (Silver Spring) 2012; doi: 10.1038/ oby.2012.45.
2. Sato S, Fukasawa M, Yamakawa Y, Natsume T, Suzuki T, Shoji I, et al. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem 2006;139:921-930.
3. Congiu M, Ryan MC, Desmond PV. No
J. Pivko, P. Makovický, A. Makarevich, A. Sirotkin, P. Makovický and E. Kubovičová
. Li, M., Song, J., Mirkov, S., Xiao, S. Y., Hart, J., Liu, W., 2011: Comparing morphometric, biochemical and visual measurements of macrovesicular steatosis of liver. Hum. Pathol., 42, 356-360.
18. Mak, K. M., Kwong, A. J., Chu, E., Hoo, N. M., 2012: Hepatic steatosis, fibrosis and cancer in elderly cadavers. Anat. Rec., 295, 40-50.
19. Makovicky, P., Dudova, M., Tumova, E., Rajmon, R., Vodkova, Z., 2011: Experimental study of non-alcoholic fatty liver disease (NAFLD) on a model of starving chickens: is generalization of steatosis
Jolanta Zalejska–Fiolka, Aleksandra Kasperczyk, Sławomir Kasperczyk, Barbara Stawiarska-Pięta, Rafał Fiolka and Ewa Birkner
1. Bandsma R.H., Wiegman C.H., Herling A.W., Burger H.J., ter Harmsel A., Meijer A.J., Romjin J.A., Reijngoud D.J., Kuipers F.: Acute inhibition of glucose- 6-phoshpate translocator acitvity leads to increase de novo lipogenesis and development of hepatic steatosis without VLDL production in rats. Diabetes 2001, 50, 2591-2597.
2. Champe P.C., Harvey R.A.: Biochemistry, Philadelphia, USA, 1994.
3. Choe E., Min D.B.: Chemistry of deep-fat frying oils. J Food Sci 2007, 72 77
Raluca Costina Dina, Maria Moţa, Iulia Vladu and Ciprian A. Dina
Introduction.Hepatic steatosis is a reversible condition caused by accumulation oftriglycerides in liver cells. Non-alcoholic fatty liver disease (NAFLD) can progressto advanced liver disease: fibrosis, cirrhosis, liver failure, cancer, and finally canlead to death; therefore NAFLD contributes significantly to morbidity and mortalityof hepatic cause. Materials and methods: The study was conducted on a group of 88patients with Body Mass Index (BMI) ≥ 30kg/m², they were excluded patients withknown diabetes. Results, Discussion: The statistical analysis showed that in morethan half of subjects elastometry values were higher than those considered normal,obesity is a risk factor for NAFLD that progresses in hepatic fibrosis. Conclusions:Liver fibrosis is present in high percentage in patients with obesity (52% of subjects)and it was positively correlated with age, arterial stiffness and fasting glucose.
currently investigated in clinical trials, including obeticholic acid, liraglutide, elafibranor, and aramchol are being evaluated ( 10 ). Lifestyle modification focused on diet and exercises continue to be the primary treatment ( 11 ). The American Association for the Study of Liver Diseases practice guideline suggests the loss of at least 3–5% of body weight to improve steatosis, and up to 10% to improve necroinflammation ( 12 ). However, most patients who ask medical advice have a long history of ineffective attempts at dietary and lifestyle changes ( 13 ). Furthermore
Daniela Maria Hurjui, Otilia Niţă, Lidia Iuliana Graur, Dana Ştefana Popescu, Laura Mihalache, Cătălin Ilie Huţanaşu and Mariana Graur
, atherosclerosis, and aspects of insulin action. Diabetes Care 28: 2312-2319, 2005.
18. Targher G, Bertolini L, Scala L et al . Nonalcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men. Role of visceral adipose tissue. Diabet Med 22: 1354-1358, 2005.
19. Savage DB, Petersen KF, Shulman GI . Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 87: 507-520, 2007.
20. Cnop M, Landchild MJ, Vidal J et al. The
Elena Caceaune, Daniela Licăroiu, O. Brădescu, N. Caceaune and C. Ionescu-Tîrgovişte
1. Angulo P . Nonalcoholic Fatty Liver Disease. The New England Journal of Medicine Vol. 346, No. 16: 1221-1231, 2002.
2. Festi D, Colecchia A, Sacco T, Bondi M, Roda E and Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity reviews 5: 27-42, 2004.
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl 1): S99-S112, 2006.
4. Szczepaniak LS, Nurenberg P, Leonard D
Barbara Stawiarska-Pięta, Jolanta Zalejska-Fiolka, Magdalena Wyszyńska, Anna Kleczka, Beata Janiga, Natalia Grzegorzak and Ewa Birkner
1. Berliner J.A., Heinecke W.J.: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996, 20, 707–727.
2. Brukow K.G.: Oxidized lipids: The two faces of vascular inflammation. Curr Atheroscler Rep 2006, 8, 223–231.
3. Bukol-Krawczyk K.: Nonalcoholic steatosis of the liver – to treat or not to treat? Forum Metabol Disord 2010, 1, 66–72.
4. Choe E., Min D.B.: Chemistry of deep-fat frying oils. J Food Sci 2007, 72, 77–86.
5. Cohn J.: Oxidized fat in the diet, postprandial lipaemia and cardiovascular